Commission Implementing Decision (EU) 2018/945 of 22 June 2018 on the communicable diseases and related special health issues to be covered by epidemiological surveillance as well as relevant case definitions (Text with EEA relevance) (c. 945)

ANNEX II U.K.

3. CASE DEFINITIONS OF COMMUNICABLE DISEASES U.K.

3.5. CHIKUNGUNYA VIRUS DISEASE U.K.

Clinical Criteria (1) U.K.

• Fever

Laboratory Criteria (2) U.K.

A. Probable case U.K.

• Detection of chikungunya specific IgM antibodies in a single serum sample.

B. Confirmed case U.K.

At least one of the following four:

• Isolation of chikungunya virus from a clinical specimen;

• Detection of chikungunya viral nucleic acid from a clinical specimen;

• Detection of chikungunya specific IgM antibodies in a single serum sample AND confirmation by neutralisation;

• Seroconversion or four-fold antibody titre increase of chikungunya specific antibodies in paired serum samples.

Epidemiological Criteria U.K.

History of travel to, or residence in an area with documented on-going transmission of chikungunya, within the two-week period prior to the onset of symptoms

Case Classification U.K.

A.

Possible case NA

B.

Probable case

Any person meeting the clinical and the epidemiological criteria, and the laboratory criteria for a probable case

C.

Confirmed case

Any person meeting the laboratory criteria for a confirmed case

Note: Serological results should be interpreted according to previous exposure to other flaviviral infections and the flavivirus vaccination status. Confirmed cases in such situations should be validated by serum neutralization assay or other equivalent assays. U.K.

(1)

Clinical criteria should be interpreted by taking into account the presence of an alternative diagnosis that can fully explain the illness.

(2)

Serological results should be interpreted according to previous exposure to other alphaviral infections.